Celldex Therapeutics (CLDX) Competitors $22.46 +0.44 (+2.00%) Closing price 08/22/2025 04:00 PM EasternExtended Trading$22.78 +0.32 (+1.42%) As of 08/22/2025 07:44 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock CLDX vs. ALKS, LGND, FOLD, BCRX, NVAX, DVAX, INVA, MNKD, OPK, and GERNShould you be buying Celldex Therapeutics stock or one of its competitors? The main competitors of Celldex Therapeutics include Alkermes (ALKS), Ligand Pharmaceuticals (LGND), Amicus Therapeutics (FOLD), BioCryst Pharmaceuticals (BCRX), Novavax (NVAX), Dynavax Technologies (DVAX), Innoviva (INVA), MannKind (MNKD), OPKO Health (OPK), and Geron (GERN). These companies are all part of the "biotechnology" industry. Celldex Therapeutics vs. Its Competitors Alkermes Ligand Pharmaceuticals Amicus Therapeutics BioCryst Pharmaceuticals Novavax Dynavax Technologies Innoviva MannKind OPKO Health Geron Alkermes (NASDAQ:ALKS) and Celldex Therapeutics (NASDAQ:CLDX) are both medical companies, but which is the better investment? We will compare the two businesses based on the strength of their earnings, institutional ownership, profitability, analyst recommendations, risk, valuation, dividends and media sentiment. Which has higher earnings & valuation, ALKS or CLDX? Alkermes has higher revenue and earnings than Celldex Therapeutics. Celldex Therapeutics is trading at a lower price-to-earnings ratio than Alkermes, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioAlkermes$1.56B3.15$367.07M$2.0814.30Celldex Therapeutics$7.02M212.47-$157.86M-$3.01-7.46 Which has more volatility & risk, ALKS or CLDX? Alkermes has a beta of 0.47, suggesting that its stock price is 53% less volatile than the S&P 500. Comparatively, Celldex Therapeutics has a beta of 1.22, suggesting that its stock price is 22% more volatile than the S&P 500. Is ALKS or CLDX more profitable? Alkermes has a net margin of 23.15% compared to Celldex Therapeutics' net margin of -3,446.88%. Alkermes' return on equity of 24.86% beat Celldex Therapeutics' return on equity.Company Net Margins Return on Equity Return on Assets Alkermes23.15% 24.86% 17.14% Celldex Therapeutics -3,446.88%-27.61%-26.20% Do insiders & institutionals hold more shares of ALKS or CLDX? 95.2% of Alkermes shares are held by institutional investors. 4.4% of Alkermes shares are held by insiders. Comparatively, 4.4% of Celldex Therapeutics shares are held by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth. Does the media prefer ALKS or CLDX? In the previous week, Alkermes had 6 more articles in the media than Celldex Therapeutics. MarketBeat recorded 24 mentions for Alkermes and 18 mentions for Celldex Therapeutics. Alkermes' average media sentiment score of 0.75 beat Celldex Therapeutics' score of 0.07 indicating that Alkermes is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Alkermes 11 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Celldex Therapeutics 2 Very Positive mention(s) 1 Positive mention(s) 7 Neutral mention(s) 4 Negative mention(s) 0 Very Negative mention(s) Neutral Do analysts recommend ALKS or CLDX? Alkermes presently has a consensus target price of $41.08, suggesting a potential upside of 38.10%. Celldex Therapeutics has a consensus target price of $46.67, suggesting a potential upside of 107.78%. Given Celldex Therapeutics' higher probable upside, analysts clearly believe Celldex Therapeutics is more favorable than Alkermes.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Alkermes 0 Sell rating(s) 3 Hold rating(s) 8 Buy rating(s) 1 Strong Buy rating(s) 2.83Celldex Therapeutics 0 Sell rating(s) 2 Hold rating(s) 7 Buy rating(s) 0 Strong Buy rating(s) 2.78 SummaryAlkermes beats Celldex Therapeutics on 13 of the 16 factors compared between the two stocks. Get Celldex Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for CLDX and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding CLDX and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart CLDX vs. The Competition Export to ExcelMetricCelldex TherapeuticsMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$1.46B$3.11B$5.76B$9.58BDividend YieldN/A2.23%4.41%4.10%P/E Ratio-7.4620.8831.1026.05Price / Sales212.47356.38435.79105.95Price / CashN/A43.1937.7358.48Price / Book2.288.129.536.61Net Income-$157.86M-$54.72M$3.26B$265.56M7 Day Performance-11.92%2.63%2.09%1.97%1 Month Performance-5.91%2.78%2.81%-0.36%1 Year Performance-39.57%11.01%30.56%19.03% Celldex Therapeutics Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)CLDXCelldex Therapeutics1.6948 of 5 stars$22.46+2.0%$46.67+107.8%-36.3%$1.46B$7.02M-7.46150News CoverageAnalyst ForecastALKSAlkermes4.7857 of 5 stars$26.54-0.6%$41.08+54.8%+6.3%$4.41B$1.56B12.761,800Trending NewsAnalyst RevisionLGNDLigand Pharmaceuticals4.1427 of 5 stars$147.01-2.0%$157.00+6.8%+53.5%$2.90B$167.13M-36.7580Positive NewsShort Interest ↓High Trading VolumeFOLDAmicus Therapeutics4.3654 of 5 stars$6.66-1.5%$16.22+143.6%-35.0%$2.08B$528.29M-55.50480News CoveragePositive NewsBCRXBioCryst Pharmaceuticals4.2514 of 5 stars$8.20-1.2%$16.70+103.7%+7.9%$1.74B$450.71M-45.55530NVAXNovavax4.6293 of 5 stars$8.04-4.0%$15.86+97.4%-34.4%$1.36B$682.16M3.521,990Analyst ForecastDVAXDynavax Technologies4.5199 of 5 stars$10.48+1.5%$24.33+132.2%-6.9%$1.24B$277.25M-22.78350News CoverageAnalyst ForecastINVAInnoviva4.5205 of 5 stars$19.64+7.1%$42.75+117.6%+8.2%$1.15B$358.71M63.36100Positive NewsHigh Trading VolumeMNKDMannKind3.3604 of 5 stars$3.42-2.9%$9.71+184.3%-22.9%$1.08B$285.50M31.07400OPKOPKO Health4.4628 of 5 stars$1.30+4.0%$2.75+111.5%-12.4%$992.23M$713.10M-5.202,997Gap UpGERNGeron3.1772 of 5 stars$1.36+6.3%$4.19+207.9%-67.4%$816.66M$76.99M-10.46229Gap Up Related Companies and Tools Related Companies Alkermes Alternatives Ligand Pharmaceuticals Alternatives Amicus Therapeutics Alternatives BioCryst Pharmaceuticals Alternatives Novavax Alternatives Dynavax Technologies Alternatives Innoviva Alternatives MannKind Alternatives OPKO Health Alternatives Geron Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:CLDX) was last updated on 8/23/2025 by MarketBeat.com Staff From Our PartnersMarket Panic: Trump Just Dropped a Bomb on Your Stockstock Market Panic: Trump Just Dropped a Bomb on Your Stocks The market is in freefall—and Trump's new tarif...American Alternative | SponsoredBONUS GUIDE - Ben Stein Prepares For the Next Financial CrisisWith inflation high, debt soaring, and global tensions rising, a financial storm may be brewing. Economist ...Goldco Precious Metals | SponsoredAlex’s “Next Magnificent Seven” stocksThe original “Magnificent Seven” turned $7K into $1.18 million. Now, Alex Green has identified AI’s Next Ma...The Oxford Club | SponsoredGENIUS Act: Cancel Your Money?A new law called the GENIUS Act could quietly trigger the most radical shift in American finance in decades. B...Priority Gold | SponsoredElon’s Secret Social Security BombshellTo All Americans Born Before April 16th, 1963: Did Trump Just Give The Green Light To Radically RE-DO Social S...Banyan Hill Publishing | SponsoredThe $7 company helping Nvidia build the world’s first trillion-dollar robot …Michael Robinson has been at the forefront of the technology market for over 40 years. Spotting some profit...Weiss Ratings | SponsoredINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredOut of 18,347 Cryptocurrencies... This is the ONLY OneThe Single Most Undervalued DeFi Protocol You've Never Heard Of If there's one cryptocurrency you should b...Crypto 101 Media | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Celldex Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Celldex Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
MarketBeat All Access